Nomura Holdings’s Myriad Genetics MYGN Stock Holding History

Nomura Holdings’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-25,000	Closed	-$953K	–	2554
2014 Q3	$953K	Sell	25,000 -1,300,000	-98%	-$48.5M	﹤0.01%	1464
2014 Q2	$51M	Buy	1,325,000 +25,000	+2%	+$930K	0.01%	151
2014 Q1	$44.7M	Buy	1,300,000 +300,000	+30%	+$9.29M	0.01%	155
2013 Q4	$21M	Sell	1,000,000 -500,000	-33%	-$12.6M	0.1%	121
2013 Q3	$35.6M	Buy	+1,500,000	New	+$42.6M	0.21%	81

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nomura Holdings's MYGN Position: Q2 2019 in Review

Nomura Holdings sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 36,400 shares — an estimated $1.21M sold.

Nomura Holdings first reported a position in MYGN in Q3 2013 and held it in 8 quarters. The position peaked at $3.36M in Q4 2013. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

Nomura Holdings reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
Nomura Holdings sold 36,400 Myriad Genetics shares in Q2 2019, an estimated $1.21M.
Nomura Holdings first reported a position in Myriad Genetics in Q3 2013 and held it in 8 quarters.
Nomura Holdings's Myriad Genetics position peaked at $3.36M in Q4 2013.
235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Nomura Holdings's 13F filing for Q2 2019, filed 14 Aug 2019.